Delineating the dystopian nature of the cell cycle in cancer
Delineating the dystopian nature of the cell cycle in cancer
批准号:
10355878
负责人:
Erik Knudsen
金额:
$54.94万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-06-03 至 2027-05-31
关键词:
AblationAutomobile DrivingBiochemicalBiologicalBreast Cancer cell lineCCNE1 geneCDK4 geneCancer ModelCancer cell lineCell CycleCell Cycle DeregulationCell Cycle ProgressionCell Cycle RegulationCell modelCellsClinicComplexComputer ModelsCoupledCyclin D1CyclinsDataDependenceEventEvolutionFDA approvedFoundationsG1 PhaseGene ExpressionGenesHeterogeneityInterventionLeadMalignant NeoplasmsMammalian CellModelingMolecularNatureOncogenesOncogenicPathway interactionsPharmaceutical PreparationsPharmacologyPhosphorylationPhosphotransferasesPlayPrimary NeoplasmProcessResistanceRoleSignal TransductionSpecimenTherapeuticTherapeutic InterventionTissuesTumor TissueWorkXenograft procedurecancer cellclinically relevantclinically significantin vivoinhibitormalignant breast neoplasmnovel strategiesoncogene addictionresponsetargeted treatmenttherapeutic targettherapy resistanttooltriple-negative invasive breast carcinomatumortumorigenic
中文摘要
点击翻译按钮获取中文摘要
英文摘要
ABSTRACT: In the classical mammalian cell cycle model, CDK and cyclin complexes are responsible for
driving specific events in a sequential fashion. Mitogenic or oncogenic signals drive the activation of CDK4/6
complexes that initiate cell cycle progression. These complexes promote RB phosphorylation that leads to the
expression of a highly conserved cadre of genes that are required for progression through the remainder of the
cell cycle. The concept put forward by this model is that cell cycle control is linear and highly predictable.
However, recent findings related to the inter-dependencies of CDK/cyclins illustrate the need for better
understanding the cell cycle repertoires that are operable in tumors. In preliminary data using unbiased and
targeted approaches we have interrogated the extent to which the “utopian” simple version of the cell cycle
breaks-down. This work indicates that in cancer models there are multiple different cell cycle modes, which
have significance for tumorigenic proliferation and therapeutic interventions. Here we will take an integrated
approach to fundamentally understand “dystopian” cell cycle states (Aim 1) and define mechanisms of collateral
therapeutic resistance and new vulnerabilities (Aim 2) which associate with non-canonical cell cycle states.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Impact of RB activation on the pancreatic cancer epigenome and tumor microenvironment
-
批准号:10673462
-
项目类别:
-
资助金额:$50.52万
-
财政年份:2023
-
负责人:Erik Knudsen
-
依托单位:
Delineating the dystopian nature of the cell cycle in cancer
-
批准号:10634518
-
项目类别:
-
资助金额:$53.84万
-
财政年份:2022
-
负责人:Erik Knudsen
-
依托单位:
RB tumor suppressor as a therapeutic target in ER-positive breast cancer
-
批准号:10775865
-
项目类别:
-
资助金额:$35.13万
-
财政年份:2020
-
负责人:Erik Knudsen
-
依托单位:
RB tumor suppressor as a therapeutic target in ER-positive breast cancer
-
批准号:10116343
-
项目类别:
-
资助金额:$42.95万
-
财政年份:2020
-
负责人:Erik Knudsen
-
依托单位:
RB tumor suppressor as a therapeutic target in ER-positive breast cancer
-
批准号:10579888
-
项目类别:
-
资助金额:$42.09万
-
财政年份:2020
-
负责人:Erik Knudsen
-
依托单位:
RB tumor suppressor as a therapeutic target in ER-positive breast cancer
-
批准号:10436675
-
项目类别:
-
资助金额:$35.13万
-
财政年份:2020
-
负责人:Erik Knudsen
-
依托单位:
RB tumor suppressor as a therapeutic target in ER-positive breast cancer
-
批准号:10358589
-
项目类别:
-
资助金额:$42.09万
-
财政年份:2020
-
负责人:Erik Knudsen
-
依托单位:
Role of the RB Tumor Suppression in Liver Tumorigenesis
-
批准号:9663130
-
项目类别:
-
资助金额:$44.08万
-
财政年份:2018
-
负责人:Erik Knudsen
-
依托单位:
Common Genetically Altered Pathways as Targets for Therapy in Pancreatic Cancer
-
批准号:10088419
-
项目类别:
-
资助金额:$39.3万
-
财政年份:2017
-
负责人:Erik Knudsen
-
依托单位:
Regulation of non-proteolytic ubiquitination in cancer chemoresistance and progression
-
批准号:10407385
-
项目类别:
-
资助金额:$38.48万
-
财政年份:2017
-
负责人:Erik Knudsen
-
依托单位:
Pathway heterogeneity: etiology and treatment of TNBC
-
批准号:9307751
-
项目类别:
-
资助金额:$15.36万
-
财政年份:2014
-
负责人:Erik Knudsen
-
依托单位:
Pathway heterogeneity: etiology and treatment of TNBC
-
批准号:8767039
-
项目类别:
-
资助金额:$32.99万
-
财政年份:2014
-
负责人:Erik Knudsen
-
依托单位:
Pathway Heterogeneity: Etiology and Treatment of TNBC
-
批准号:9663639
-
项目类别:
-
资助金额:$16.49万
-
财政年份:2014
-
负责人:Erik Knudsen
-
依托单位:
Impact of Cyclin D1 Isoforms in Breast Cancer
-
批准号:8118447
-
项目类别:
-
资助金额:$35.07万
-
财政年份:2010
-
负责人:Erik Knudsen
-
依托单位:
Impact of Cyclin D1 Isoforms in Breast Cancer
-
批准号:8448558
-
项目类别:
-
资助金额:$32.99万
-
财政年份:2010
-
负责人:Erik Knudsen
-
依托单位:
Action of RB Pathway in Breast Cancer Therapy
-
批准号:8103142
-
项目类别:
-
资助金额:$31.19万
-
财政年份:2010
-
负责人:Erik Knudsen
-
依托单位:
Action of RB Pathway in Breast Cancer Therapy
-
批准号:8453468
-
项目类别:
-
资助金额:$30.08万
-
财政年份:2010
-
负责人:Erik Knudsen
-
依托单位:
Impact of Cyclin D1 Isoforms in Breast Cancer
-
批准号:8638897
-
项目类别:
-
资助金额:$34.04万
-
财政年份:2010
-
负责人:Erik Knudsen
-
依托单位:
Action of RB Pathway in Breast Cancer Therapy
-
批准号:8719536
-
项目类别:
-
资助金额:$5.32万
-
财政年份:2010
-
负责人:Erik Knudsen
-
依托单位:
Action of RB Pathway in Breast Cancer Therapy
-
批准号:8254476
-
项目类别:
-
资助金额:$31.2万
-
财政年份:2010
-
负责人:Erik Knudsen
-
依托单位:
海外基金